ABSTRACT
Subclinical hypothyroidism (SH) is a frequent condition affecting millions of people around the world. Defined by increased thyrotropin-stimulating hormone (TSH) and accompanied by normal thyroid hormone levels, SH reflects a mild tissue hypothyroidism that has been associated with metabolic derangements and—although this issue is still contentious—possibly with increased cardiovascular risk. Depending on the degree of TSH elevation, SH has accordingly been associated with hyperlipidemia, arterial hypertension, and cardiovascular disease (CVD), as well as, increasingly, newly emerging CVD risk factors such as serum C-reactive protein and retinol binding protein 4 levels. There have also been reports of abnormalities in glucose metabolism and of hemostatic parameters, mainly underscored by the increased activity of factor VII. This review discusses the results of the latest studies on the various parameters affected by SH while highlighting the need for timely treatment with levothyroxine.
KEYWORDS
Subclinical hypothyroidism - TSH - hemostasis - cardiovascular risk
REFERENCES
-
1
Biondi B, Cooper D S.
The clinical significance of subclinical thyroid dysfunction.
Endocr Rev.
2008;
29
(1)
76-131
-
2
Tunbridge W M, Evered D C, Hall R et al.
The spectrum of thyroid disease in a community: the Whickham survey.
Clin Endocrinol (Oxf).
1977;
7
(6)
481-493
-
3
Hollowell J G, Staehling N W, Flanders W D et al.
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).
J Clin Endocrinol Metab.
2002;
87
(2)
489-499
-
4
Canaris G J, Manowitz N R, Mayor G, Ridgway E C.
The Colorado thyroid disease prevalence study.
Arch Intern Med.
2000;
160
(4)
526-534
-
5
Duntas L H, Wartofsky L.
Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence?.
Thyroid.
2007;
17
(11)
1075-1084
-
6
Li Y, Shan Z, Teng W et al.
Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months.
Clin Endocrinol (Oxf).
2010;
72
(6)
825-829
-
7
Vanderpump M P, Tunbridge W M, French J M et al.
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.
Clin Endocrinol (Oxf).
1995;
43
(1)
55-68
-
8
Duntas L H.
Subclinical hypothyroidism: a misnomer in search of a new name.
Thyroid.
2001;
11
(4)
361-362
-
9
Surks M I, Ortiz E, Daniels G H et al.
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.
JAMA.
2004;
291
(2)
228-238
-
10
Boucai L, Surks M I.
Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice.
Clin Endocrinol (Oxf).
2009;
70
(5)
788-793
-
11
Karmisholt J, Andersen S, Laurberg P.
Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism.
Thyroid.
2008;
18
(3)
303-308
-
12
Andersen S, Bruun N H, Pedersen K M, Laurberg P.
Biologic variation is important for interpretation of thyroid function tests.
Thyroid.
2003;
13
(11)
1069-1078
-
13
Vigário P, Teixeira P, Reuters V et al.
Perceived health status of women with overt and subclinical hypothyroidism.
Med Princ Pract.
2009;
18
(4)
317-322
-
14
McMillan C, Bradley C, Razvi S, Weaver J.
Evaluation of new measures of the impact of hypothyroidism on quality of life and symptoms: the ThyDQoL and ThySRQ.
Value Health.
2008;
11
(2)
285-294
-
15
Fazio S, Palmieri E A, Lombardi G, Biondi B.
Effects of thyroid hormone on the cardiovascular system.
Recent Prog Horm Res.
2004;
59
31-50
-
16
Biondi B, Klein I.
Hypothyroidism as a risk factor for cardiovascular disease.
Endocrine.
2004;
24
(1)
1-13
-
17
Cappola A R, Ladenson P W.
Hypothyroidism and atherosclerosis.
J Clin Endocrinol Metab.
2003;
88
(6)
2438-2444
-
18
Biondi B, Palmieri E A, Lombardi G, Fazio S.
Effects of subclinical thyroid dysfunction on the heart.
Ann Intern Med.
2002;
137
(11)
904-914
-
19
Biondi B, Palmieri E A, Lombardi G, Fazio S.
Subclinical hypothyroidism and cardiac function.
Thyroid.
2002;
12
(6)
505-510
-
20
Biondi B, Fazio S, Palmieri E A et al.
Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism.
J Clin Endocrinol Metab.
1999;
84
(6)
2064-2067
-
21
Brenta G, Mutti L A, Schnitman M, Fretes O, Perrone A, Matute M L.
Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy.
Am J Cardiol.
2003;
91
(11)
1327-1330
-
22
Rodondi N, Newman A B, Vittinghoff E et al.
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.
Arch Intern Med.
2005;
165
(21)
2460-2466
-
23
Rodondi N, Bauer D C, Cappola A R et al.
Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study.
J Am Coll Cardiol.
2008;
52
(14)
1152-1159
-
24
Ripoli A, Pingitore A, Favilli B et al.
Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study.
J Am Coll Cardiol.
2005;
45
(3)
439-445
-
25
Nagasaki T, Inaba M, Kumeda Y et al.
Increased pulse wave velocity in subclinical hypothyroidism.
J Clin Endocrinol Metab.
2006;
91
(1)
154-158
-
26
Owen P JD, Rajiv C, Vinereanu D, Mathew T, Fraser A G, Lazarus J H.
Subclinical hypothyroidism, arterial stiffness, and myocardial reserve.
J Clin Endocrinol Metab.
2006;
91
(6)
2126-2132
-
27
Taddei S, Caraccio N, Virdis A et al.
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy.
J Clin Endocrinol Metab.
2003;
88
(8)
3731-3737
-
28
Hak A E, Pols H A, Visser T J, Drexhage H A, Hofman A, Witteman J C.
Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.
Ann Intern Med.
2000;
132
(4)
270-278
-
29
Imaizumi M, Akahoshi M, Ichimaru S et al.
Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism.
J Clin Endocrinol Metab.
2004;
89
(7)
3365-3370
-
30
Walsh J P, Bremner A P, Bulsara M K et al.
Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.
Arch Intern Med.
2005;
165
(21)
2467-2472
-
31
Vanderpump M P, Tunbridge W M.
Epidemiology and prevention of clinical and subclinical hypothyroidism.
Thyroid.
2002;
12
(10)
839-847
-
32
Cappola A R, Fried L P, Arnold A M et al.
Thyroid status, cardiovascular risk, and mortality in older adults.
JAMA.
2006;
295
(9)
1033-1041
-
33
Ochs N, Auer R, Bauer D C et al.
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.
Ann Intern Med.
2008;
148
(11)
832-845
-
34
Razvi S, Shakoor A, Vanderpump M, Weaver J U, Pearce S H.
The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis.
J Clin Endocrinol Metab.
2008;
93
(8)
2998-3007
-
35
Gussekloo J, van Exel E, de Craen A J, Meinders A E, Frölich M, Westendorp R G.
Thyroid status, disability and cognitive function, and survival in old age.
JAMA.
2004;
292
(21)
2591-2599
-
36
van den Beld A W, Visser T J, Feelders R A, Grobbee D E, Lamberts S W.
Thyroid hormone concentrations, disease, physical function, and mortality in elderly men.
J Clin Endocrinol Metab.
2005;
90
(12)
6403-6409
-
37
Klieverik L P, Coomans C P, Endert E et al.
Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo.
Endocrinology.
2009;
150
(12)
5639-5648
-
38
Figueroa B, Vélez H, Irizarry-Ramírez M.
Association of thyroid-stimulating hormone levels and body mass index in overweight Hispanics in Puerto Rico.
Ethn Dis.
2008;
18
(2, Suppl 2)
S2-S151-4
-
39
Resta O, Pannacciulli N, Di Gioia G, Stefàno A, Barbaro M P, De Pergola G.
High prevalence of previously unknown subclinical hypothyroidism in obese patients referred to a sleep clinic for sleep disordered breathing.
Nutr Metab Cardiovasc Dis.
2004;
14
(5)
248-253
-
40
Asvold B O, Bjøro T, Vatten L J.
Association of serum TSH with high body mass differs between smokers and never-smokers.
J Clin Endocrinol Metab.
2009;
94
(12)
5023-5027
-
41
Rotondi M, Leporati P, La Manna A et al.
Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism?.
Eur J Endocrinol.
2009;
160
(3)
403-408
-
42
Reinehr T.
Obesity and thyroid function.
Mol Cell Endocrinol.
2010;
316
(2)
165-171
-
43
De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R.
Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women.
Clin Endocrinol (Oxf).
2007;
67
(2)
265-269
-
44
Tagliaferri M, Berselli M E, Calò G et al.
Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile.
Obes Res.
2001;
9
(3)
196-201
-
45
Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A.
Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH).
Clin Endocrinol (Oxf).
2008;
69
(6)
963-969
-
46
Rodrigues A L, de Moura E G, Passos M C, Dutra S C, Lisboa P C.
Postnatal early overnutrition changes the leptin signalling pathway in the hypothalamic-pituitary-thyroid axis of young and adult rats.
J Physiol.
2009;
587
(Pt 11)
2647-2661
-
47
Ruhla S, Weickert M O, Arafat A M et al.
A high normal TSH is associated with the metabolic syndrome.
Clin Endocrinol (Oxf).
2010;
72
(5)
696-701
-
48
Zimmermann M B, Aeberli I, Melse-Boonstra A et al.
Iodine treatment in children with subclinical hypothyroidism due to chronic iodine deficiency decreases thyrotropin and C-peptide concentrations and improves the lipid profile.
Thyroid.
2009;
19
(10)
1099-1104
-
49
Scarabottolo L, Trezzi E, Roma P, Catapano A L.
Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver.
Atherosclerosis.
1986;
59
(3)
329-333
-
50
Duntas L H.
Thyroid disease and lipids.
Thyroid.
2002;
12
(4)
287-293
-
51
Brenta G, Berg G, Zago V et al.
Proatherogenic mechanisms in subclinical hypothyroidism: hepatic lipase activity in relation to the VLDL remnant IDL.
Thyroid.
2008;
18
(11)
1233-1236
-
52
Kim C S, Kang J G, Lee S J et al.
Relationship of low-density lipoprotein (LDL) particle size to thyroid function status in Koreans.
Clin Endocrinol (Oxf).
2009;
71
(1)
130-136
-
53
Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver J U.
The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial.
J Clin Endocrinol Metab.
2007;
92
(5)
1715-1723
-
54
Monzani F, Caraccio N, Kozàkowà M et al.
Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study.
J Clin Endocrinol Metab.
2004;
89
(5)
2099-2106
-
55
Danese M D, Ladenson P W, Meinert C L, Powe N R.
Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.
J Clin Endocrinol Metab.
2000;
85
(9)
2993-3001
-
56
Palmieri E A, Fazio S, Lombardi G, Biondi B.
Subclinical hypothyroidism and cardiovascular risk: a reason to treat?.
Treat Endocrinol.
2004;
3
(4)
233-244
-
57
Christ-Crain M, Meier C, Guglielmetti M et al.
Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial.
Atherosclerosis.
2003;
166
(2)
379-386
-
58
Kvetny J, Heldgaard P E, Bladbjerg E M, Gram J.
Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years.
Clin Endocrinol (Oxf).
2004;
61
(2)
232-238
-
59
Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K.
Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia.
Endocr J.
2005;
52
(1)
89-94
-
60
Lee W Y, Suh J Y, Rhee E J, Park J S, Sung K C, Kim S W.
Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status.
Arch Med Res.
2004;
35
(6)
540-545
-
61
Burba I, Devanna P, Pesce M.
When cells become a drug. Endothelial progenitor cells for cardiovascular therapy: aims and reality.
Recent Patents Cardiovasc Drug Discov.
2010;
5
(1)
1-10
-
62
Shakoor S K, Aldibbiat A, Ingoe L E et al.
Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy.
J Clin Endocrinol Metab.
2010;
95
(1)
319-322
-
63
Wolf G.
Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes.
Nutr Rev.
2007;
65
(5)
251-256
-
64
Choi S H, Lee Y J, Park Y J et al.
Retinol binding protein-4 elevation is associated with serum thyroid-stimulating hormone level independently of obesity in elderly subjects with normal glucose tolerance.
J Clin Endocrinol Metab.
2008;
93
(6)
2313-2318
-
65
Franchini M, Montagnana M, Manzato F, Vescovi P P.
Thyroid dysfunction and hemostasis: an issue still unresolved.
Semin Thromb Hemost.
2009;
35
(3)
288-294
-
66
Squizzato A, Romualdi E, Büller H R, Gerdes V E.
Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review.
J Clin Endocrinol Metab.
2007;
92
(7)
2415-2420
-
67
Erem C.
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Clin Endocrinol (Oxf).
2006;
64
(3)
323-329
-
68
Mina A, Favaloro E J, Koutts J.
Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.
Semin Thromb Hemost.
2007;
33
(8)
798-809
-
69
Müller B, Tsakiris D A, Roth C B, Guglielmetti M, Staub J J, Marbet G A.
Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease.
Eur J Clin Invest.
2001;
31
(2)
131-137
-
70
Ermantas N, Guldiken S, Demir M, Tugrul A.
Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Clin Appl Thromb Hemost.
2010;
16
(5)
568-573
-
71
Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G.
Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
J Clin Endocrinol Metab.
2001;
86
(2)
732-737
-
72
Chadarevian R, Jublanc C, Bruckert E et al.
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
J Endocrinol Invest.
2005;
28
(5)
398-404
-
73
Gullu S, Sav H, Kamel N.
Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism.
Eur J Endocrinol.
2005;
152
(3)
355-361
-
74
Jorde R, Figenschau Y, Hansen J B.
Haemostatic function in subjects with mild subclinical hypothyroidism. The Tromsø study.
Thromb Haemost.
2006;
95
(4)
750-751
-
75
Biondi B.
Should we treat all subjects with subclinical thyroid disease the same way?.
Eur J Endocrinol.
2008;
159
(3)
343-345
Leonidas H DuntasM.D.
Professor of Endocrinology, Endocrine Unit, Evgenidion Hospital, University of Athens
20 Papadiamantopoulou Street, 115 28 Athens, Greece
Email: ledunt@otenet.gr
